Developer docs
API playgroundTry for free, no card

Search company profiles

VistaPath Biosystems

Full company profile

uuid0002css

Namestring
VistaPath Biosystems
Legal namestring
Vistapath Biosystems, Inc.
Websiteurl
vistapath.ai
Company typeenum
Private
Founded yearint
2017
Descriptiontext

VistaPath Biosystems is a privately held medical-technology company founded in 2017 and headquartered in Cambridge, Massachusetts. The company develops the Sentinel platform, an AI-powered automated tissue grossing system for anatomical pathology laboratories. Sentinel uses computer vision and machine learning to photograph, measure, and document tissue samples in under one second, generating gross reports that the company reports are produced 90%+ faster than manual methods with 43% greater accuracy. The platform includes modular add-ons — Link for workflow management, Merge for multi-vial cassette consolidation, Confirm for chain-of-custody and automated QA, and Consult for remote specialist collaboration — that extend coverage from grossing through digital sign-out. The system is ISO 27001 certified and FDA 21 CFR Part 11 compliant, and integrates with laboratory information systems (LIS) and EMR data.

VistaPath serves commercial pathology laboratories, hospital-based pathology departments, contract research organizations, and life sciences companies. Named customers and validation partners include PathGroup (12-unit deployment at its centralized Nashville, TN laboratory), Freedom Pathology Laboratories (Savannah, GA), and PathAI. The company sells through direct enterprise field sales supplemented by strategic partnerships and a demo-request channel for mid-market labs.

The business model combines hardware placement (sale or lease of Sentinel units) with usage-based per-sample billing, with VistaPath retaining responsibility for ongoing platform upkeep and maintenance. Pricing is quote-based and not publicly disclosed. The company has raised approximately $8.9M in disclosed venture funding from Moxxie Ventures, First Star Ventures, NextGen Venture Partners, Cota Capital, and ValueStream Ventures. Leadership comprises CEO and co-founder Tim Spong (15-year histotechnologist), COO and co-founder Ben Burley, CTO Jacob Guggenheim (MIT PhD, Human-Machine systems), and VP of Sales and Marketing J. Fernando Corredor.

Short descriptiontext

VistaPath Biosystems develops the Sentinel platform, an AI-powered automated tissue grossing system that uses computer vision to photograph, measure, and document pathology specimens. It serves commercial labs, hospitals, CROs, and life sciences companies via hardware placement and per-sample usage pricing.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersCambridge, United States
HQ citystring
Cambridge
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
digital pathology automation, AI tissue grossing, computer vision pathology, anatomical pathology workflow, laboratory workflow software
Industry1 code
PRIMARYHLAGAJAM
Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
NAICS code1 code
  • Analytical Laboratory Instrument Manufacturing334516
SIC code2 codes
  • Laboratory Analytical Instruments3826
  • Surgical & Medical Instruments & Apparatus3841
Product category
Digital Pathology Automation Software
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Per-Sample Usage Billing
TypeUsage Based
Description

Labs pay per sample processed through the Sentinel platform, providing a scalable, consumption-based revenue model. Vistapath manages all platform upkeep and maintenance.

vistapath.ai
2Hardware Device Sales
TypeHardware Sales
Description

Sale or lease of Sentinel hardware units to laboratories, with Vistapath managing ongoing platform maintenance.

vistapath.ai
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations, Infrastructure
Pricing details1 tier
1Per-sample pricing model
ModelUsage-basedBilling cadencePay-as-you-go
Notes

Labs pay per sample processed; Vistapath manages all platform upkeep. Specific pricing tiers not publicly disclosed.

vistapath.ai
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 record
1Sentinel
Description

The world's first automated tissue grossing platform that uses AI and computer vision to optimize pathology workflows, generating gross reports faster and more accurately than traditional methods.

vistapath.ai
Core offering1 text field

VistaPath Biosystems develops and sells the Sentinel automated tissue grossing platform, an AI-powered computer vision system that photographs, measures, and documents anatomical pathology tissue samples for clinical and research laboratories. The platform integrates with laboratory information systems (LIS) and EMR data via the proprietary SentinelOS and is sold alongside modular add-ons (Sentinel Link, Merge, Confirm, and Consult) that handle workflow management, multi-vial cassette consolidation, chain-of-custody QA, and remote specialist consultation. Customers include commercial pathology laboratories, hospital pathology departments, contract research organizations (CROs), and life sciences companies.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 90%+ faster end-to-end grossing process
+3 more records
Product overview1 text field

Vistapath offers the Sentinel platform, an end-to-end digital grossing solution comprising a core automated tissue grossing platform plus modular add-ons. The main Sentinel product provides AI-powered tissue grossing with computer vision and automation. The Sentinel ecosystem includes Link (workflow management), Merge (cassette consolidation), Confirm (chain of custody/QA), and Consult (remote collaboration) modules, all designed to modernize pathology labs by delivering higher quality, efficiency, and consistency across critical lab processes.

Product and service5 records
1Sentinel Automated Tissue Grossing Platform
CategoryDigital pathology automation
Description

End-to-end AI-powered automated tissue grossing platform that uses computer vision to receive, assess, photograph, measure, and document tissue specimens. Measures samples in under one second, generates gross reports 90%+ faster than manual methods, and integrates with laboratory information systems (LIS) and EMR data; targets commercial pathology labs, hospital pathology departments, CROs, and life sciences research laboratories.

2Sentinel Link
CategoryPathology workflow management software
Description

Secure, web-based platform that lets lab assistants image and document specimens at the bench with the Sentinel device, generating structured gross reports in real time for review and approval by certified grossing personnel or pathologists.

3Sentinel Merge
CategoryPathology workflow management software
Description

AI-powered feature that consolidates specimens from multiple vials of tissue into a single unified cassette using AI measurement and tracking, reducing labor costs, turnaround times, and downstream reagent usage while preserving reimbursement.

4Sentinel Confirm
CategoryPathology quality assurance software
Description

Automated quality assurance and chain-of-custody module that provides time-stamped events and embedded QA, ensuring complete, consistent case context for pathologists during digital sign-out.

5Sentinel Consult
CategoryPathology collaboration software
Description

Real-time remote collaboration module that enables labs to securely live broadcast cases via Sentinel Workspace for specialist consultation, staff training, and practice standardization without travel.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-12-17
Description

Freedom Pathology Laboratories in Savannah, Georgia deployed the Sentinel platform. The deployment enhanced grossing process efficiency, reduced errors, and improved specimen handling consistency. The deployment demonstrated minimal onboarding requirements for technicians.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-11-13
Description

PathGroup deployed 12 Sentinel AI-powered grossing platforms at their centralized laboratory in Nashville, TN. This major enterprise deployment strengthens PathGroup's commitment to innovation and diagnostic precision. The partnership represents an important step in modernizing pathology grossing workflows at scale.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2022-09-16
Description

VistaPath and PathAI collaborated to validate the Sentinel automated tissue grossing platform in a clinical setting. PathAI validated the Sentinel in their clinical workflow, establishing it as a validated AI-powered grossing solution. This partnership charted the course for broader clinical market adoption following FDA and ISO27001 compliance.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2022-07-28
Description

Collaboration combining VistaPath's Sentinel automated tissue grossing platform with Gestalt's AI Requisition Engine (AIRE) to advance pathology digitization. The partnership integrates automated grossing with AI-powered accessioning to improve front-end laboratory workflow speed and accuracy.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

AI-powered digital pathology platform serving pharma, diagnostic labs, and pathology practices. Directly comparable as a clinical AI pathology vendor and is both a current VistaPath partner and a potential competitor in the same pathology AI category.

TypeDirect peer
Description

Provides AI-driven pathology workflow and requisition software (PathFlow, AIRE) for hospital and commercial labs. Directly comparable as a pathology digitization partner and VistaPath's existing integration collaborator for front-end accessioning workflows.

TypeDirect peer
Description

Digital pathology software platform with AI applications for diagnostic and research pathology labs. Comparable as a software-led pathology workflow vendor targeting similar commercial lab and biopharma customers with an overlapping AI/computer-vision stack.

TypeDirect peer
Description

AI-powered cancer diagnostics platform deployed in pathology labs worldwide for clinical decision support. Directly comparable as an AI pathology vendor serving commercial and hospital labs, with overlapping computer-vision and lab workflow integration requirements.

TypeDirect peer
Description

AI image analysis platform for pathology and other life-science microscopy. Comparable as an AI computer-vision vendor to pathology and life-sciences customers, with overlapping use cases in tissue-based diagnostics and research workflows.

TypeBroad incumbent
Description

Global leader in tissue diagnostics through its Ventana Digital Pathology portfolio, serving the same hospital and commercial lab customers. Comparable as a broad incumbent with much larger scale that could enter or bundle automated grossing offerings.

TypeBroad incumbent
Description

Operates the IntelliSite Pathology Solution for whole-slide imaging and digital workflows in hospital pathology. Comparable as a broad incumbent digital pathology vendor with established enterprise sales reach into VistaPath's target accounts.

TypeBroad incumbent
Description

Major supplier of histology instruments, consumables, and digital pathology solutions (Aperio) used by hospital and commercial labs. Comparable as a broad incumbent with deep relationships in the same grossing and histology workflow VistaPath targets.

TypeEmerging player
Description

Spatial biology and multiplex tissue analysis platform with growing pathology lab footprint. Comparable as an emerging tissue-analysis vendor pursuing pathology and life-sciences customers with adjacent AI and imaging capabilities.

TypeEmerging player
Description

AI-driven pathology and biopharma analytics company serving research and clinical pathology use cases. Comparable as an emerging player in AI-enabled tissue analysis with overlapping life-sciences and pathology customers.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration2 records

Each record includes

Title, Type, Description, Source

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

VistaPath Biosystems

Digital Pathology Automation Softwarevistapath.ai

VistaPath Biosystems develops the Sentinel platform, an AI-powered automated tissue grossing system that uses computer vision to photograph, measure, and document pathology specimens. It serves commercial labs, hospitals, CROs, and life sciences companies via hardware placement and per-sample usage pricing.

What VistaPath Biosystems does

VistaPath Biosystems is a privately held medical-technology company founded in 2017 and headquartered in Cambridge, Massachusetts. The company develops the Sentinel platform, an AI-powered automated tissue grossing system for anatomical pathology laboratories. Sentinel uses computer vision and machine learning to photograph, measure, and document tissue samples in under one second, generating gross reports that the company reports are produced 90%+ faster than manual methods with 43% greater accuracy. The platform includes modular add-ons — Link for workflow management, Merge for multi-vial cassette consolidation, Confirm for chain-of-custody and automated QA, and Consult for remote specialist collaboration — that extend coverage from grossing through digital sign-out. The system is ISO 27001 certified and FDA 21 CFR Part 11 compliant, and integrates with laboratory information systems (LIS) and EMR data.

VistaPath serves commercial pathology laboratories, hospital-based pathology departments, contract research organizations, and life sciences companies. Named customers and validation partners include PathGroup (12-unit deployment at its centralized Nashville, TN laboratory), Freedom Pathology Laboratories (Savannah, GA), and PathAI. The company sells through direct enterprise field sales supplemented by strategic partnerships and a demo-request channel for mid-market labs.

The business model combines hardware placement (sale or lease of Sentinel units) with usage-based per-sample billing, with VistaPath retaining responsibility for ongoing platform upkeep and maintenance. Pricing is quote-based and not publicly disclosed. The company has raised approximately $8.9M in disclosed venture funding from Moxxie Ventures, First Star Ventures, NextGen Venture Partners, Cota Capital, and ValueStream Ventures. Leadership comprises CEO and co-founder Tim Spong (15-year histotechnologist), COO and co-founder Ben Burley, CTO Jacob Guggenheim (MIT PhD, Human-Machine systems), and VP of Sales and Marketing J. Fernando Corredor.

VistaPath Biosystems firmographics

Firmographics
Name
VistaPath Biosystems
Legal name
Vistapath Biosystems, Inc.
Website
https://vistapath.ai
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
11–50 employees
Short description
VistaPath Biosystems develops the Sentinel platform, an AI-powered automated tissue grossing system that uses computer vision to photograph, measure, and document pathology specimens. It serves commercial labs, hospitals, CROs, and life sciences companies via hardware placement and per-sample usage pricing.
Ownership category
akta.pro rank

VistaPath Biosystems industry classification

Industry
Product category
Digital Pathology Automation Software
NAICS
Analytical Laboratory Instrument Manufacturing (334516)
SIC
Laboratory Analytical Instruments (3826), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAGAJAM
Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)

Keywords

  • Digital pathology automation
  • AI tissue grossing
  • Computer vision pathology
  • Anatomical pathology workflow
  • Laboratory workflow software

Where VistaPath Biosystems is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United States
HQ region
North America

Offices1 record

Markets served

VistaPath Biosystems business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations, Infrastructure

Revenue model

  1. Per-Sample Usage Billing: Labs pay per sample processed through the Sentinel platform, providing a scalable, consumption-based revenue model. Vistapath manages all platform upkeep and maintenance.
  2. Hardware Device Sales: Sale or lease of Sentinel hardware units to laboratories, with Vistapath managing ongoing platform maintenance.

Pricing tiers

ModelBillingPrice
Usage-basedPay-as-you-goPer-sample pricing model

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

VistaPath Biosystems product offering

Product offering

Core offering

VistaPath Biosystems develops and sells the Sentinel automated tissue grossing platform, an AI-powered computer vision system that photographs, measures, and documents anatomical pathology tissue samples for clinical and research laboratories. The platform integrates with laboratory information systems (LIS) and EMR data via the proprietary SentinelOS and is sold alongside modular add-ons (Sentinel Link, Merge, Confirm, and Consult) that handle workflow management, multi-vial cassette consolidation, chain-of-custody QA, and remote specialist consultation. Customers include commercial pathology laboratories, hospital pathology departments, contract research organizations (CROs), and life sciences companies.

Product overview

Vistapath offers the Sentinel platform, an end-to-end digital grossing solution comprising a core automated tissue grossing platform plus modular add-ons. The main Sentinel product provides AI-powered tissue grossing with computer vision and automation. The Sentinel ecosystem includes Link (workflow management), Merge (cassette consolidation), Confirm (chain of custody/QA), and Consult (remote collaboration) modules, all designed to modernize pathology labs by delivering higher quality, efficiency, and consistency across critical lab processes.

Differentiator

Problem solved

Functional benefit

Brands

  • Sentinel: The world's first automated tissue grossing platform that uses AI and computer vision to optimize pathology workflows, generating gross reports faster and more accurately than traditional methods.

Products and services

  • Sentinel Automated Tissue Grossing Platform End-to-end AI-powered automated tissue grossing platform that uses computer vision to receive, assess, photograph, measure, and document tissue specimens. Measures samples in under one second, generates gross reports 90%+ faster than manual methods, and integrates with laboratory information systems (LIS) and EMR data; targets commercial pathology labs, hospital pathology departments, CROs, and life sciences research laboratories.
  • Sentinel Link Secure, web-based platform that lets lab assistants image and document specimens at the bench with the Sentinel device, generating structured gross reports in real time for review and approval by certified grossing personnel or pathologists.
  • Sentinel Merge AI-powered feature that consolidates specimens from multiple vials of tissue into a single unified cassette using AI measurement and tracking, reducing labor costs, turnaround times, and downstream reagent usage while preserving reimbursement.
  • Sentinel Confirm Automated quality assurance and chain-of-custody module that provides time-stamped events and embedded QA, ensuring complete, consistent case context for pathologists during digital sign-out.
  • Sentinel Consult Real-time remote collaboration module that enables labs to securely live broadcast cases via Sentinel Workspace for specialist consultation, staff training, and practice standardization without travel.

Quantifiable outcome

  • 90%+ faster end-to-end grossing process
  • +3 more outcomes

Companies that use VistaPath Biosystems

Customer profile

Named customers3 records

Segments4 records

Ideal customer profiles4 records

VistaPath Biosystems technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability5 records

Feature6 records

VistaPath Biosystems partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and flagship.

  • Freedom Pathology LaboratoriescoreStrategic or Co-development Partner · 17 December 2025Freedom Pathology Laboratories in Savannah, Georgia deployed the Sentinel platform. The deployment enhanced grossing process efficiency, reduced errors, and improved specimen handling consistency. The deployment demonstrated minimal onboarding requirements for technicians.
  • PathGroupflagshipStrategic or Co-development Partner · 13 November 2025PathGroup deployed 12 Sentinel AI-powered grossing platforms at their centralized laboratory in Nashville, TN. This major enterprise deployment strengthens PathGroup's commitment to innovation and diagnostic precision. The partnership represents an important step in modernizing pathology grossing workflows at scale.
  • PathAIcoreTechnology or Integration · 16 September 2022VistaPath and PathAI collaborated to validate the Sentinel automated tissue grossing platform in a clinical setting. PathAI validated the Sentinel in their clinical workflow, establishing it as a validated AI-powered grossing solution. This partnership charted the course for broader clinical market adoption following FDA and ISO27001 compliance.
  • Gestalt DiagnosticscoreTechnology or Integration · 28 July 2022Collaboration combining VistaPath's Sentinel automated tissue grossing platform with Gestalt's AI Requisition Engine (AIRE) to advance pathology digitization. The partnership integrates automated grossing with AI-powered accessioning to improve front-end laboratory workflow speed and accuracy.

Scale indicators4 records

Recent moves6 records

Expansion highlights4 records

VistaPath Biosystems competitors and assessment

Company assessment

Direct peers

  • PathAI: AI-powered digital pathology platform serving pharma, diagnostic labs, and pathology practices. Directly comparable as a clinical AI pathology vendor and is both a current VistaPath partner and a potential competitor in the same pathology AI category.
  • Gestalt Diagnostics: Provides AI-driven pathology workflow and requisition software (PathFlow, AIRE) for hospital and commercial labs. Directly comparable as a pathology digitization partner and VistaPath's existing integration collaborator for front-end accessioning workflows.
  • Proscia: Digital pathology software platform with AI applications for diagnostic and research pathology labs. Comparable as a software-led pathology workflow vendor targeting similar commercial lab and biopharma customers with an overlapping AI/computer-vision stack.
  • Ibex Medical Analytics: AI-powered cancer diagnostics platform deployed in pathology labs worldwide for clinical decision support. Directly comparable as an AI pathology vendor serving commercial and hospital labs, with overlapping computer-vision and lab workflow integration requirements.
  • Aiforia: AI image analysis platform for pathology and other life-science microscopy. Comparable as an AI computer-vision vendor to pathology and life-sciences customers, with overlapping use cases in tissue-based diagnostics and research workflows.

Broad incumbents

  • Roche (Ventana): Global leader in tissue diagnostics through its Ventana Digital Pathology portfolio, serving the same hospital and commercial lab customers. Comparable as a broad incumbent with much larger scale that could enter or bundle automated grossing offerings.
  • Philips Digital Pathology: Operates the IntelliSite Pathology Solution for whole-slide imaging and digital workflows in hospital pathology. Comparable as a broad incumbent digital pathology vendor with established enterprise sales reach into VistaPath's target accounts.
  • Leica Biosystems: Major supplier of histology instruments, consumables, and digital pathology solutions (Aperio) used by hospital and commercial labs. Comparable as a broad incumbent with deep relationships in the same grossing and histology workflow VistaPath targets.

Emerging players

  • Akoya Biosciences: Spatial biology and multiplex tissue analysis platform with growing pathology lab footprint. Comparable as an emerging tissue-analysis vendor pursuing pathology and life-sciences customers with adjacent AI and imaging capabilities.
  • Owkin: AI-driven pathology and biopharma analytics company serving research and clinical pathology use cases. Comparable as an emerging player in AI-enabled tissue analysis with overlapping life-sciences and pathology customers.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks7 records

Key highlights7 records

Customer concentration

VistaPath Biosystems social profiles

Digital presence

VistaPath Biosystems compliance and trust

Trust signal

Compliance2 records

VistaPath Biosystems financial estimates

Financial estimate

Revenue estimate

Valuation estimate

VistaPath Biosystems leadership team

Management profile

Number of profiles

Profiles4 records

VistaPath Biosystems funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

VistaPath Biosystems M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about VistaPath Biosystems

What does VistaPath Biosystems do?

VistaPath Biosystems develops and sells the Sentinel automated tissue grossing platform, an AI-powered computer vision system that photographs, measures, and documents anatomical pathology tissue samples for clinical and research laboratories. The platform integrates with laboratory information systems (LIS) and EMR data via the proprietary SentinelOS and is sold alongside modular add-ons (Sentinel Link, Merge, Confirm, and Consult) that handle workflow management, multi-vial cassette consolidation, chain-of-custody QA, and remote specialist consultation. Customers include commercial pathology laboratories, hospital pathology departments, contract research organizations (CROs), and life sciences companies.

Is VistaPath Biosystems a public or private company?

VistaPath Biosystems is a private company. It is classified as venture growth investor backed and is currently operating.

When was VistaPath Biosystems founded?

VistaPath Biosystems was founded in 2017. It employs 11 to 50 people.

Where is VistaPath Biosystems based?

VistaPath Biosystems is headquartered in Cambridge, United States, in the North America region.

How does VistaPath Biosystems make money?

Two revenue lines are on record. Per-Sample Usage Billing is the primary driver. The others are hardware Device Sales.

Who are VistaPath Biosystems's main competitors?

Direct peers on record are PathAI, Gestalt Diagnostics, Proscia, Ibex Medical Analytics and Aiforia. Broad incumbents are Roche (Ventana), Philips Digital Pathology and Leica Biosystems. Emerging players are Akoya Biosciences and Owkin.

Does VistaPath Biosystems have an API?

No public API is recorded for VistaPath Biosystems.

What industry is VistaPath Biosystems in?

VistaPath Biosystems's product category is Digital Pathology Automation Software. Its primary akta.pro industry code is HLAGAJAM, Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF). Its NAICS code is 334516 and its SIC code is 3826.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
SecSEC FORM DVistaPath Biosystems, Inc. filed a Form D with the SEC to report an exempt securities offering under Rule 506(b), with total proceeds of $5,663,426 USD. The filing indicates that $4,442,495 has been sold to five investors as of June 22, 2023. This regulatory submission serves as a notification of the capital raise activity rather than a market-moving commercial event.PR NewswireVistaPath Launches New Collaboration with Gestalt Diagnostics to Further Accelerate Pathology DigitizationVistaPath and Gestalt Diagnostics announced a collaboration to enhance AI-driven digitization in pathology laboratories by integrating VistaPath's Sentinel platform and Gestalt's AIRE algorithm. The partnership aims to improve speed, accuracy, and traceability in pathology workflows through AI solutions.FinSMEsVistaPath Raises $4M in Seed FundingVistaPath, a Cambridge, Mass.-based AI pathology platform provider, raised $4 million in seed funding led by Moxxie Ventures with participation from NextGen Venture Partners and First Star Ventures. The company will use the funds to expand operations and development, with additional applications slated for release later this year.BioSpaceVistaPath Raises $4M to Modernize Pathology Labs Using Computer Vision and Artificial IntelligenceVistaPath secured $4 million in seed funding led by Moxxie Ventures to advance its AI-based pathology processing platforms. The company's flagship product, Sentinel, utilizes computer vision to automate tissue grossing, reportedly achieving 93% faster processing and 43% greater accuracy than human technicians. This capital will support the full-scale development of existing products and the release of additional applications later this year.